![Medicinal Cannabis Draws Eyes as Oil Slides and Bond Yields Climb [FTSE AIM UK 50 INDEX]](https://cedclinic.com/wp-content/uploads/2026/06/ced-unsplash-ke6jYtwXDKA-1-150x150.jpg "Medicinal Cannabis Draws Eyes as Oil Slides and Bond Yields Climb [FTSE AIM UK 50 INDEX] 13")
#47 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
Understanding the terpene profiles of specific cannabis strains like Strawberry Cough helps clinicians counsel patients on expected effects and side effects, since terpenes influence therapeutic potency and psychoactive properties beyond THC and CBD alone. Patients self-selecting strains based on flavor may inadvertently be choosing products with distinct pharmacological profiles, making terpene education essential for optimizing symptom management and minimizing adverse effects. This knowledge gap between strain selection and actual biochemical effects represents a critical opportunity to improve patient safety and treatment outcomes in cannabis-using populations.
Strawberry Cough is a cannabis strain whose distinctive sensory profile is primarily determined by its terpene composition, the aromatic compounds that contribute to both flavor and potential therapeutic effects. Understanding the terpene profile of specific strains is clinically relevant because terpenes may modulate cannabinoid effects through the entourage effect and can independently contribute to symptom relief, particularly for anxiety, mood, and pain management. For clinicians recommending cannabis products to patients, awareness of strain-specific terpene profiles allows for more personalized treatment selection based on desired effects and patient-specific symptom targets. Different terpene combinations may explain why individual patients report varying therapeutic responses to ostensibly similar THC/CBD ratios across different products. Clinicians should educate patients that product selection should consider the full chemical profile beyond cannabinoid content alone, as terpene composition significantly influences both efficacy and side effect profiles. Requesting detailed laboratory analysis of terpene content from dispensaries or manufacturers can help patients and providers make more informed, individualized cannabis medicine decisions.
🌿 While consumer-facing strain guides like this one highlight the terpene profiles that drive cannabis flavor and aroma, clinicians should recognize that terpene composition alone is an incomplete predictor of clinical effects or individual patient response. The article’s focus on sensory characteristics, though useful for patient preferences, does not address cannabinoid potency, entourage effects, or the substantial interindividual variability in metabolism and sensitivity that influences therapeutic outcomes and adverse events. Additionally, terpene profiles can vary significantly between cultivators and growing conditions, making strain-based recommendations inherently unstable as a clinical tool. When counseling patients about cannabis use—whether for symptom management or harm reduction—providers should emphasize that strain names and terpene descriptions offer limited clinical guidance, and instead encourage patients to track their own dose, THC/CBD content, and subjective response to inform safer use.
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
